Patents by Inventor Michael Greif

Michael Greif has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 7378262
    Abstract: The invention relates to a composition comprising a first modified thermostable enzyme exhibiting 3?exonuclease activity but essentially no DNA polymerase activity and a second modified thermostable enzyme exhibiting DNA polymerase activity, whereas the fidelity of an amplification process is enhanced by the use of the composition in an amplification process in comparison to the use of the single second enzyme in an amplification process and, whereas said first and said second modified thermostable enzyme is reversibly modified by an inhibiting agent which results in essentially complete inactivation of enzyme activity, wherein incubation of said first and said second modified thermostable enzyme in an aqueous buffer at alkaline pH at a temperature less than 25° C. for 20 minutes results in no significant increase in the activity of said first and said second modified thermostable enzyme, wherein incubation at a temperature greater than 50° C.
    Type: Grant
    Filed: December 11, 2002
    Date of Patent: May 27, 2008
    Assignee: Roche Molecular Systems, Inc.
    Inventors: Harald Sobek, Michael Greif
  • Patent number: 7030220
    Abstract: A purified thermostable enzyme is derived from the thermophilic archaebacterium Archaeoglobus fulgidus. The enzyme can be native or recombinant, is stable under PCR conditions and exhibits double strand specific exonuclease activity. It is a 3?–5? exonuclease and cleaves to produce 5?-mononucleotides. Thermostable exonucleases are useful in many recombinant DNA techniques, in combination with a thermostable DNA polymerase like Tag especially for nucleic acid amplification by the polymerase chain reaction (PCR).
    Type: Grant
    Filed: September 27, 2000
    Date of Patent: April 18, 2006
    Assignees: Roche Diagnostics GmbH, Roche Molecular Systems Inc.
    Inventors: Waltraud Ankenbauer, Frank Laue, Harald Sobek, Michael Greif
  • Publication number: 20060078928
    Abstract: A purified thermostable enzyme is derived form the thermophilic archaebacterium Archaeoglobus fulgidus. The enzyme can be native or recombinant, is stable under PCR conditions and exhibits double strand specific exonuclease activity. It is a 3?-5? exonuclease and cleaves to produce 5?-mononucleotides. Thermostable exonucleases are useful in many recombinant DNA techniques, in combination with a thermostable DNA polymerase like Taq especially for nucleic acid amplification by the polymerase chain reaction (PCR).
    Type: Application
    Filed: September 29, 2005
    Publication date: April 13, 2006
    Applicants: Roche Diagnostics GmbH, Roche Molecular Systems Inc.
    Inventors: Waltraud Ankenbauer, Frank Laue, Harald Sobek, Michael Greif
  • Publication number: 20040115639
    Abstract: The invention relates to a composition comprising a first modified thermostable enzyme exhibiting 3′exonuclease activity but essentially no DNA polymerase activity and a second modified thermostable enzyme exhibiting DNA polymerase activity, whereas the fidelity of an amplification process is enhanced by the use of the composition in an amplification process in comparison to the use of the single second enzyme in an amplification process and, whereas said first and said second modified thermostable enzyme is reversibly modified by an inhibiting agent which results in essentially complete inactivation of enzyme activity, wherein incubation of said first and said second modified thermostable enzyme in an aqueous buffer at alkaline pH at a temperature less than 25° C. for 20 minutes results in no significant increase in the activity of said first and said second modified thermostable enzyme, wherein incubation at a temperature greater than 50° C.
    Type: Application
    Filed: December 11, 2002
    Publication date: June 17, 2004
    Applicant: Roche Molecular Systems, Inc.
    Inventors: Harald Sobek, Michael Greif